BioHarvest Sciences Awarded $1.6 Million USD Grant from the Israeli Innovation Authority to Advance Second-Generation Botanical Synthesis Platform
MWN-AI** Summary
BioHarvest Sciences Inc. has received a significant boost by being awarded a $1.6 million USD grant from the Israeli Innovation Authority (IIA). This funding, part of the IIA's Bio-Convergence program, which promotes interdisciplinary technologies, will bolster the development of BioHarvest's second-generation Botanical Synthesis™ platform. The grant is non-dilutive, meaning it won’t impact the company's equity, preserving its financial health notably as the company maintains around $25 million in cash.
The funding will primarily focus on several innovative enhancements within BioHarvest's operations. Key areas of development include the incorporation of artificial intelligence for enhanced process optimization and analytics, scaling up bioreactor sizes to improve production volume and economics, and expanding autonomous manufacturing functionalities to ensure greater efficiency and reproducibility.
Ilan Sobel, CEO of BioHarvest, emphasized that the grant represents both a validation of their technological prowess and a strategic advantage for financial stability, allowing the firm to advance its manufacturing capabilities without the pressure of diluting equity. The grant operates as a zero-interest loan contingent on the company achieving specific commercial milestones, creating a pathway to positive revenue streams from the ongoing project.
BioHarvest is positioned as a leader in botanical synthesis, uniquely producing plant-based compounds through controlled plant cell culture without traditional agricultural dependencies. This approach not only aligns with their commitment to sustainable practices but also strengthens their service offerings in the health and wellness sector, encompassing both contract development and proprietary nutraceutical products.
As the company progresses, this grant reaffirms their strategic direction while fortifying their financial standing and operational capabilities.
MWN-AI** Analysis
BioHarvest Sciences Inc. (NASDAQ: BHST), which recently secured a $1.6 million grant from the Israeli Innovation Authority (IIA), presents an intriguing investment opportunity that merits careful consideration. This non-dilutive funding will significantly bolster BioHarvest's development of its proprietary Botanical Synthesis™ platform, a notable advancement in biotechnology that merges plant-based production with cutting-edge technology.
The grant aligns with BioHarvest's strategic direction, allowing the company to enhance its operational capabilities without diluting shareholder equity. By integrating artificial intelligence for process optimization and expanding bioreactor sizes, BioHarvest can potentially scale up production and improve unit economics, positioning itself favorably in the competitive biotech landscape.
A strong cash position, with approximately $25 million on hand, combined with this grant, solidifies BioHarvest’s financial health. This funding will not only sustain ongoing projects but also empower the company to innovate further, potentially leading to the commercialization of novel plant-based compounds in high-demand sectors such as health and wellness. The non-dilutive nature of the grant reduces financial risk for current investors, making it an attractive proposition for those seeking growth in the biotech field.
Moreover, as the company is recognized within the Bio-Convergence domain, it showcases its commitment to addressing contemporary challenges through innovative solutions that synthesize biology with engineering and data science. This multifaceted approach could position BioHarvest as a leader in the industry, especially as consumer demand for sustainable and plant-based products continues to rise.
Investors should monitor BioHarvest's progress closely, focusing on the execution of its strategic initiatives and the successful integration of AI and automation within its production processes. Given the launch of its second-generation manufacturing capabilities, BioHarvest could experience significant growth and market traction in the near future, making it an investment worth considering.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - December 18, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a biotechnology company pioneering its proprietary Botanical Synthesis™ platform, today announced that it has been awarded a $1.6 million grant from the Israeli Innovation Authority (IIA). The grant was approved under the IIA's Bio-Convergence program, which supports technologies at the intersection of biology, engineering, data science, and artificial intelligence.
The non-dilutive funding will support the development of new innovative capabilities for BioHarvest's second-generation Botanical Synthesis™ process, enabling the Company to continue advancing its biotechnology innovation while maintaining a strong balance sheet.
The grant will be used to accelerate:
- Integration of artificial intelligence-based tools for process optimization, data analytics, and real-time decision-making
- Significant increases in bioreactor size, supporting higher-volume production and improved unit economics
- Expanded autonomous manufacturing functions, enhancing scalability, reproducibility, and operational efficiency
The Israeli Innovation Authority selected BioHarvest as one of the companies operating within the Bio-Convergence domain, recognizing the Company's differentiated approach to producing plant-based active compounds through controlled plant cell culture rather than traditional agriculture.
Importantly, as a result of prior equity transactions, BioHarvest is fully funded to execute its current strategic and operational plans and maintains a strong balance sheet with approximately $25 million in cash. The IIA grant further strengthens the Company's financial position by supporting advanced R&D without shareholder dilution.
"This non-dilutive grant from the Israeli Innovation Authority is the first received through the efforts of our Strategic Grants team, and it is both a validation of our technology leadership and a strategic financial advantage," said Ilan Sobel, CEO of BioHarvest. "It allows us to accelerate the evolution of our Botanical Synthesis™ platform by integrating AI, automation, and larger-scale bioreactors, while preserving capital and maintaining balance sheet strength as we move toward our second-generation manufacturing capabilities."
The grant was provided by the Israel Innovation Authority in the form of a non-dilutive, zero-interest loan. Repayment is contingent upon the achievement of certain predefined commercial milestones and is expected to be made solely from future revenues generated by the funded project. No equity or equity-linked instruments were issued in connection with the grant.
The Israeli Innovation Authority is a government entity dedicated to fostering Israel's innovation ecosystem by supporting companies across all stages of technology development, from early research through industrial deployment.
About BioHarvest
BioHarvest (NASDAQ: BHST) (FSE: 8MV) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and production organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products, which includes dietary supplements. To learn more, please visit www.bioharvest.com.
Forward-Looking Statements
Information set forth in this news release might include forward-looking statements that are based on management's current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHST does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.
Contacts:
BioHarvest Corporate Contact:
Dave Ryan, VP Investor Relations
+1 (604) 622-1186
info@bioharvest.com
Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
+1 (949) 259-4987
BHST@mzgroup.us
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/278495
FAQ**
How does the biotech ecosystem in Vancouver, British Columbia, compare to that of Rehovot, Israel, particularly in relation to companies like BioHarvest Sciences Inc. (NASDAQ: BHST) leveraging grants for innovation?
Given BioHarvest Sciences Inc. (BHST) received a $1.6 million grant, what are the implications of such funding for Vancouver-based biotech firms seeking similar financial support for R&D initiatives?
How might the advancements in artificial intelligence and automation, as highlighted by BioHarvest Sciences Inc. (BHST), impact the broader biotech industries in both Vancouver, BC, and Rehovot, Israel?
What strategic advantages do companies like BioHarvest Sciences Inc. (BHST) gain from non-dilutive funding in Rehovot, and how might this influence investment opportunities in Vancouver's biotech sector?
**MWN-AI FAQ is based on asking OpenAI questions about BioHarvest Sciences Inc. (NASDAQ: BHST).
NASDAQ: BHST
BHST Trading
1.65% G/L:
$4.31 Last:
2,343 Volume:
$4.275 Open:
